GlassScriptPhysician profile
Claire Bravo
NPI 1477847309
$1,451.68
in general payments reported to CMS, 2019-2025
16 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $104 · 2021: $539 · 2022: $207 · 2023: $184 · 2024: $126 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $258.33 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $250.80 | 2021-2025 | |
| Therapeuticsmd, INC. | $218.69 | 2019-2022 | |
| Evofem Biosciences, INC. | $198.61 | 2020-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $115.57 | 2021-2023 | |
| Lupin INC. | $75.04 | 2019 | |
| Becton, Dickinson and Company | $65.20 | 2021-2023 | Bd Onclarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.93 | 2021 | |
| Sage Therapeutics, LLC | $47.14 | 2025 | Zurzuvae |
| Scynexis, INC. | $40.47 | 2022 | |
| Abbott Laboratories | $27.27 | 2024 | Freestyle Libre 3 |
| Duchesnay USA Incorporated | $24.05 | 2019 | |
| Exeltis, USA INC. | $23.05 | 2024 | Slynd |
| Supernus Pharmaceuticals, INC. | $20.06 | 2025 | Qelbree |
| Coopersurgical, INC. | $18.82 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.